•  
  •  
  •  
  •  

2025-06-18 11:28:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Rachit Prints Limited receives in-principle approval from BSE SME Exchange, Plans to Raise ₹19.50 Crore
  • UGRO Capital Ltd to acquire 100% stake in Profectus Capital Pvt Ltd
  • Bihar CM Nitish Kumar inaugurates Bhupatipur-Punpun elevated road, built by Afcons
  • Equity Shares of Indosolar Ltd to list in NSE and BSE from June 19, 2025
  • ITCONS E-Solutions Limited receives new work orders from HCL Technologies Ltd

Keywords Selected:  INE901L01018

Stock Report

  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Amlodipine and Atorvastatin Tablets USP
  • Alembic Pharmaceuticals receives USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg
  • Alembic Pharmaceuticals Ltd recommends dividend of Rs. 11
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
  • Alembic Pharmaceuticals Ltd commissions new facility at Pithampur
  • Alembic Pharmaceuticals receives USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Pantoprazole Sodium for Injection, 40 mg/vial - Single-Dose Vial
  • Alembic Pharmaceuticals Ltd successfully completes USFDA inspection for API-III facility
  • USFDA inspection at Alembic Pharma's Bioequivalence Facility
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
  • Alembic Pharmaceuticals Limited passes ANVISA, Brazil GMP audit for its API-II Facility at Panelav
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg
  • Alembic Pharmaceuticals Ltd's Oncology facility successfully completes USFDA inspection
  • Alembic Pharmaceuticals announces USFDA Final Approval for Lamotrigine ExtendedRelease Tablets USP, 200 mg, 250 mg, and 300 mg
  • US FDA inspection at Alembic Pharmaceuticals Limited' Oral Solid Formulation Facility at Panelav
  • Alembic Pharmaceuticals announces USFDA Final Approval for Paliperidone Extended Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Albendazole Tablets USP, 200 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Betamethasone Valerate Foam, 0.12%
  • Alembic Pharmaceuticals announces USFDA Final Approval for Nelarabine Injection, 250 mg/50 mL
  • Successful completion of USFDA inspection at Alembic Pharmaceuticals Ltd' Oral Solid Formulation Facility (F-I) at Panelav
  • Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg
  • Alembic Pharmaceuticals announces USFDA Tentative Approval for Selexipag for Injection, 1,800 mcg/vial
  • Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%

Latest Post

  • Rachit Prints Limited receives in-principle approval from BSE SME Exchange, Plans to Raise ₹19.50 Crore
  • UGRO Capital Ltd to acquire 100% stake in Profectus Capital Pvt Ltd
  • Bihar CM Nitish Kumar inaugurates Bhupatipur-Punpun elevated road, built by Afcons
  • Equity Shares of Indosolar Ltd to list in NSE and BSE from June 19, 2025
  • ITCONS E-Solutions Limited receives new work orders from HCL Technologies Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024